Montelukast Pharmathen (Montelukast)

Montelukast selectively blocks the cysteinyl leukotriene receptor CysLT1 on airway cells. By antagonizing this receptor, it stops leukotrienes from causing bronchoconstriction, mucus production, and inflammatory cell recruitment, thereby reducing airway swelling and hyper‑responsiveness.

The dose of Montelukast Pharmathen is determined by the prescribing clinician based on the patient’s age, condition severity, and response to therapy. Healthcare providers follow approved dosing guidelines, and patients should follow the prescriber’s instructions without deviation.

Safety data for Montelukast in pregnancy and lactation are limited. The prescriber should weigh potential benefits against possible risks and discuss these considerations with the patient. Breastfeeding mothers should also consult their healthcare professional before using the medication.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials. The team then replies with pricing, availability, shipping details and any required import documentation.

The primary alternative for asthma control is inhaled corticosteroids, which reduce airway inflammation directly. Montelukast, as a leukotriene receptor antagonist, offers an oral option that targets a different inflammatory pathway and can be used as add‑on therapy or when inhaled steroids are not tolerated.

Store Montelukast Pharmathen at ambient temperature below 25 °C, in its original packaging, protected from moisture and light. Keep the product out of reach of children and avoid exposing it to extreme heat or humidity.

Montelukast Pharmathen is taken orally, usually as a single tablet per day. It can be swallowed with or without food, according to the prescriber’s instructions. Consistency in timing helps maintain steady drug levels.

Serious risks include neuropsychiatric events such as agitation, depression, or suicidal thoughts, and severe allergic reactions like rash, angioedema, or anaphylaxis. Patients should seek immediate medical attention if they experience mood changes, thoughts of self‑harm, or signs of an allergic reaction.

Montelukast should be avoided in individuals with known hypersensitivity to montelukast or any of its excipients. Caution is advised for patients with severe hepatic impairment, and it is not recommended for use in children under the age approved for the specific formulation.